- 1.
OCREVUS [prescribing information]. South San Francisco, CA:
Genentech, Inc. 2020.
- 2.
Data on file. Genentech, Inc. September 2020.
- 3.
Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in
multiple sclerosis: updated analysis in patients with relapsing and
primary progressive multiple sclerosis. Poster presented at: the 35th
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS); September 11-13, 2019; Stockholm,
Sweden.
- 4.
FDA approves new drug to treat multiple sclerosis [press release].
Silver Spring, MD: Food and Drug Administration; March 29, 2017.
- 5.
De Stefano N, Giorgia A, Battaglini M, et al. Assessing brain atrophy
rates in a large population of untreated multiple sclerosis subtypes.
Neurology. 2010;74(23);1868-1876.
- 6.
Fox RJ, Cohen JA. Multiple sclerosis: the importance of early
recognition and treatment. Cleve Clin J Med.
2001;68(2):157-171.
- 7.
Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a
first demyelinating event suggestive of a multiple sclerosis prodrome:
a matched cohort study. Lancet Neurol.
2017;16(6):445-451.
- 8.
Confavreux C, Vukusic S. Natural history of multiple sclerosis: a
unifying concept. Brain. 2006;129(3):606-616.
- 9.
Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease
activity-free relapsing multiple sclerosis. Ann Neurol.
2019;85(5):653-666.
- 10.
Kantarci OH, Lebrun C, Siva A, et al. Primary progressive multiple
sclerosis evolving from radiologically isolated syndrome. Ann
Neurol. 2016;79(2):288-294.
- 11.
Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated
syndrome: 5-year risk for an initial clinical event. PLoS One.
2014 Mar 5;9(3):e90509.
- 12.
Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of
multiple sclerosis: a dynamic visualization of disease course.
Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e279.
- 13.
Zeydan B, Kantarci OH. Progressive forms of multiple sclerosis:
distinct entity or age-dependent phenomena. Neurol Clin.
2018;36(1):163-171.
- 14.
Krieger SC, Sumowski J. New insights into multiple sclerosis clinical
course from the topographical model and functional reserve. Neurol
Clin. 2018;36(1):13-25.
- 15.
De Stefano N, Narayan S, Francis GS, et al. Evidence of axonal damage
in the early stages of multiple sclerosis and its relevance to
disability. Arch Neurol. 2001;58(1)65-70.
- 16.
Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and
degeneration in multiple sclerosis. Prog Neurobiol.
2011;93(1):1-12.
- 17.
Singh S, Dallenga T, Winkler A, et al. Relationship of acute axonal
damage, Wallerian degeneration, and clinical disability in multiple
sclerosis. J Neuroinflammation. 2017;14(1):57.
- 18.
Hawker K. Progressive multiple sclerosis: characteristics and
management. Neurol Clin. 2011;29(2):423-434.
- 19.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology.
1983;33(11):1444-1452.
- 20.
Akbar N, Honarmand K, Kou N, et al. Validity of a computerized
version of the symbol digit modalities test in multiple sclerosis.
J Neurol. 2011;258(3):373-379.
- 21.
Watson TM, Ford E, Worthington E, Lincoln NB. Validation of mood
measures for people with multiple sclerosis. Int J MS Care.
2014;16(2):105-109.
- 22.
Javůrková A, Zimová D, Tomašovičová K, et al. Cognitive deficits and
neuropsychological assessment in multiple sclerosis. In
Gonzalez-Quevedo, ed. Trending Topics in Multiple Sclerosis. Rijeka,
Croatia: IntechOpen; 2016; chapter 9.
- 23.
van Munster CE, Uitdehaag BM. Outcome measures in clinical trials for
multiple sclerosis. CNS Drugs. 2017 Mar;31(3):217-236.
- 24.
Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history
of multiple sclerosis: a geographically based study 9: observations on
the progressive phase of the disease. Brain. 2006;129(Pt
3):584-594.
- 25.
Confavreux C, Vukusic S. Accumulation of irreversible disability in
multiple sclerosis: from epidemiology to treatment. Clin Neurol
Neurosurg. 2006;108(3):327-332.
- 26.
Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F, et al.
Natural history of multiple sclerosis in a population-based cohort.
Eur J Neurol. 2008;15(9):916-921.
- 27.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon
beta-1a in relapsing multiple sclerosis. N Engl J Med.
2017;376(3):221-234.
- 28.
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells
are major targets for effective immunotherapy in relapsing multiple
sclerosis. EBioMedicine. 2017;16:41-50.
- 29.
Data on file. Genentech, Inc. May 2020.
- 30.
Data on file. Genentech, Inc. July 2018.
- 31.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon
beta-1a in relapsing multiple sclerosis. N Engl J Med.
2017;376(3)(suppl):S6.
- 32.
Hauser SL, Brochet B, Montalban X, et al. Long-term reduction of
relapse rate and confirmed disability progression after 5 years of
ocrelizumab treatment in patients with relapsing multiple sclerosis.
Presented at: 34th Congress of the European Committee for Treatment
and Research in Multiple Sclerosis; October 10-12, 2018; Berlin,
Germany.
- 33.
Arnold DL, Kappos L, Hauser SL, et al. Long-term reduction in brain
MRI disease activity and atrophy after 5 years of ocrelizumab
treatment in patients with relapsing multiple sclerosis. Presented at:
34th Congress of the European Committee for Treatment and Research in
Multiple Sclerosis; October 10-12, 2018; Berlin, Germany.
- 34.
Turner B, Cree B, Kappos L, et al. Ocrelizumab efficacy in subgroups
of patients with relapsing multiple sclerosis. J
Neurol. 2019;266(5):1182-1193.
- 35.
Data on file. Genentech, Inc. April 2019.
- 36.
Hauser SL, Kappos L, Montalban X, et al. Long-term reduction in
48-week confirmed disability progression after 5 years of ocrelizumab
treatment in patients with relapsing multiple sclerosis. Presented at:
5th Congress of the European Academy of Neurology (EAN): June 29-July
2, 2019; Oslo, Norway.
- 37.
Kaunzner UW, Gauthier SA. MRI in the assessment and monitoring of
multiple sclerosis: an update on best practice. Ther Adv Neurol
Disord. 2017;10(6):247-261.
- 38.
De Seze J, Arnold DL, Bar-Or A, et al. Infusion-related reactions
with ocrelizumab in relapsing multiple sclerosis and primary
progressive multiple sclerosis. Presented at: 32nd Congress of the
European Committee for Treatment and Research of Multiple Sclerosis;
September 14-17, 2016; London, United Kingdom.
- 39.
Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in
multiple sclerosis: updated analysis in patients with relapsing and
primary progressive multiple sclerosis. Poster presented at: the 35th
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS); September 11-13, 2019; Stockholm,
Sweden.(Suppl.).
- 40.
Centers for Disease Control and Prevention. Women with disabilities
and breast cancer screening.
https://www.cdc.gov/ncbddd/disabilityandhealth/breast-cancer-screening.html.
Accessed August 20, 2019.
- 41.
American Cancer Society. American Cancer Society guidelines for the
early detection of cancer.
https://www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html.
Accessed February 15, 2019.
- 42.
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo
in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220.
- 43.
Hartung H-P. Ocrelizumab shorter infusion: primary results from the
ENSEMBLE PLUS substudy in patients with MS. Neurol Neuroimmunol
Neuroinflamm. 2020;7(5):1-9.
- 44.
Data on file. Genentech, Inc. March 2020.
- 45.
Data on file. Genentech, Inc. Zitter Group Analysis. January 2020.
